Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Receivables: 2016-2024

Historic Receivables for UroGen Pharma (URGN) over the last 6 years, with Dec 2024 value amounting to $20.3 million.

  • UroGen Pharma's Receivables fell 13.59% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.3 million, marking a year-over-year increase of 13.57%. This contributed to the annual value of $20.3 million for FY2024, which is 31.46% up from last year.
  • UroGen Pharma's Receivables amounted to $20.3 million in FY2024, which was up 31.46% from $15.4 million recorded in FY2023.
  • UroGen Pharma's 5-year Receivables high stood at $20.3 million for FY2024, and its period low was $7.0 million during FY2020.
  • Moreover, its 3-year median value for Receivables was $15.4 million (2023), whereas its average is $16.1 million.
  • Data for UroGen Pharma's Receivables shows a peak YoY soared of 66.27% (in 2021) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Receivables (Yearly) stood at $7.0 million in 2020, then surged by 66.27% to $11.7 million in 2021, then rose by 8.42% to $12.7 million in 2022, then rose by 21.56% to $15.4 million in 2023, then surged by 31.46% to $20.3 million in 2024.